Mepolizumab market seen reaching $3.21 billion by 2030

The Business Research Company says the global mepolizumab market is set to grow from $2.22 billion in 2025 to $2.38 billion in 2026, with further expansion to $3.21 billion by 2030. The report points to rising asthma cases, broader biologics use and increasing demand for targeted therapies as key drivers, with North America leading now and Asia-Pacific expected to grow fastest.

Why it matters: - The mepolizumab market is growing alongside rising asthma and eosinophilic disease burdens. - The drug class is tied to biologic therapies that aim for more targeted treatment and less reliance on systemic steroids. - The market outlook suggests continued demand for specialty respiratory care and precision medicine.

What happened: - The Business Research Company released a 2026 market report on mepolizumab covering global forecasts through 2035. - The report estimates the market will rise from $2.22 billion in 2025 to $2.38 billion in 2026, a 7.5% CAGR. - The report projects the market will reach $3.21 billion by 2030, with a 7.7% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa. - A free sample report is available here. - The full report is available here.

The details: - Mepolizumab is a humanized monoclonal antibody that blocks interleukin-5. - Interleukin-5 supports the growth, activation and survival of eosinophils. - The drug is used mainly for severe eosinophilic asthma and other eosinophilic conditions. - Mepolizumab is designed to lower exacerbation rates, improve symptom control and reduce dependence on systemic corticosteroids. - The report links market growth to rising incidence of severe asthma, stronger awareness of eosinophilic disorders, biologics research, specialty care expansion and better diagnostic tools for inflammatory disease. - Looking ahead, the report points to personalized medicine, a growing biologics pipeline, demand for home-based treatments, targeted immunotherapies and higher healthcare spending on chronic disease management. - The report highlights wider adoption of monoclonal antibody therapies, broader clinical use in eosinophilic disorders, and better adherence through targeted treatments as key trends. - The report describes biologics as advanced medicines derived from living organisms that target specific disease pathways. - The report says biologics can deliver better outcomes with fewer side effects than traditional treatments. - The Australian Institute of Health and Welfare reported in February 2026 that asthma accounted for 2.5% of Australia’s total disease burden in 2024. - AIHW said asthma was the leading cause of disease burden among children ages 1 to 9 and drove about $1.3 billion in healthcare spending in 2023-24. - AIHW also reported higher asthma prevalence and hospitalization rates among boys than girls. - NHS England said in February 2023 that about 5.4 million people in the UK were receiving asthma treatment. - NHS England said roughly 160,000 new asthma cases are diagnosed each year in the UK. - NHS England said occupational exposures account for 9% to 15% of adult-onset asthma cases. - The British Generic Manufacturers Association reported in August 2023 that UK biosimilar sales for the National Health Service are projected to reach about $33 billion between 2023 and 2028.

Between the lines: - The forecast reflects a broader shift toward precision respiratory care, where biologics are taking share from older, less targeted therapies. - The asthma burden data help explain why eosinophil-targeted drugs remain commercially relevant across developed markets. - The stronger outlook for Asia-Pacific suggests room for expansion beyond the market’s current North America base.

What's next: - The report expects continued growth as biologic adoption broadens and more patients move toward targeted treatment pathways. - Market gains will likely track future asthma prevalence, diagnostic access and healthcare investment in chronic disease management. - The report package also includes TAM analysis, company scoring matrices, forecasting dashboards, market hotspot infographics and updated graphics and tables.